Radiolabeled peptide therapy beats everolimus on progression-free survival in COMPETE

What happened

COMPETE directly compared peptide receptor radionuclide therapy with everolimus in adults with advanced, progressive, somatostatin-receptor-positive gastroenteropancreatic neuroendocrine tumors. The open-label phase 3 trial enrolled across 49 specialist centers in 14 countries and randomized 309 patients.

What the study found

Median progression-free survival was 23.9 months with lutetium-177 edotreotide and 14.1 months with everolimus. The stratified hazard ratio was 0.67. Treatment-related grade 3 or 4 adverse events occurred in 18% of patients in the radiolabeled-peptide group and 40% in the everolimus group; no treatment-related deaths were reported.

Evidence check

This is randomized phase 3 evidence with blinded central review of the primary endpoint, supporting an A grade for the comparative progression claim. The trial was open label, and its findings apply to the enrolled grade 1 or 2, receptor-positive disease population—not to cancer generally. Progression-free survival is also distinct from overall survival.

Why it matters

The peptide is functioning as a molecular address: it targets somatostatin receptors and carries radiation to tumor tissue. The result provides rare head-to-head sequencing evidence in a field where both options were already established. Treatment choice still requires specialist assessment of receptor status, disease pattern, marrow and kidney considerations.